États-Unis · Plateformes & données · MarketBeat

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Publié par MarketBeat · États-Unis il y a 1 h

Rani Therapeutics (NASDAQ:RANI) outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

À lire aussi

Forget the Anthropic IPO. Here Are 6 Stocks Worth Watching.

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Bank of Korea holds rates, upbeat outlook points to future hikes

FUN Stock Heads For 4th Week Of Loss: Analyst Sees 29% Downside Ahead Of Earnings As Mounting Debt, Weak Sales Loom

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Partager

À lire aussi

Forget the Anthropic IPO. Here Are 6 Stocks Worth Watching.

The Social Security Administration wants more babies signed up for ‘Trump accounts.’ But there’s still a catch.

Bank of Korea holds rates, upbeat outlook points to future hikes

FUN Stock Heads For 4th Week Of Loss: Analyst Sees 29% Downside Ahead Of Earnings As Mounting Debt, Weak Sales Loom

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge